Xanthohumol {90000201}

Record Keys

Parent:[  ]
Queue:[  ]


Initialisation date:
[  ]
[  ]

Meta Information

Structural Type:[  ]
Functional Type:
Energy Source


[  ]

Shared Reference Notes

  • [1.1] [#Xanthohumol supplementation
    - XN supplementation > decreased plasma insulin concentrations > improved Insulin Resistance. - The intestinal microbiota > metabolizes XN into bioactive compounds, including dihydroxanthohumol > anti-obesity. - XN > increased the relative abundance of three bacteria, Akkermansia muciniphila, Parabacteroides goldsteinii and Alistipes finegoldii.
  • [1.2
    - some of the positive outcomes of XN are accomplished by increasing #Akkermansia muciniphila, which we also found increased by TXN
  • [#Metabolic associated fatty liver disease] - XN also exhibits hepatoprotective effects in animal models of MAFLD and other liver-damaging conditions
  • [#Metabolic Dysfunction-associated Steatohepatitis] - XN and even more so, TXN, attenuates hepatosteatosis by acting as antagonists of PPARγ
  • [#Metabolic syndrome] - Xanthohumol (XN) and its derivatives mitigate diet-induced #Obesity-related characteristics of MetS in mice by improving impaired #Glucose and lipid metabolism
  • - TXN treatment also reduced levels of inflammation-inducing microbes, such as #Oscillibacter valericigenes, that lead to adverse metabolic phenotypes.
  • - TXN attenuates macrophage inflammatory processes in adipose tissue.

References Notes

[  ]

Common References

MetaBiom only uses strictly necessary session cookies to give you the best possible experience on the website. By selecting "Accept essential cookies" you agree to the use of these cookies.